Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database
- 18 December 2014
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 169 (1), 81-89
- https://doi.org/10.1111/bjh.13264
Abstract
Waldenström macroglobulinaemia (WM) is a rare and incurable lymphoma. Given that the survival of WM patients can be prolonged, our objective was to describe trends in overall survival (OS) and analyse competing risks of death in patients with WM. The analysis included 5784 patients diagnosed with WM between 1991 and 2010 from the Surveillance, Epidemiology and End Results (SEER) database. Multivariate hazard models for OS and cumulative incidence of death were fitted according to epoch of diagnosis (1991-2000 vs. 2001-10) while adjusting for age, sex, race, histology, site of involvement and registry. Median OS for the 1991-2000 and the 2001-10 cohorts was 6 and 8 years, respectively (P < 0·001). In the multivariate analysis, better OS [hazard ratio (HR) 0·73, 95% confidence interval (CI) 0·67-0·79; P < 0·001] was seen in the 2001-10 cohort. Survival benefits were identified, for the 2001-10 cohort, in almost every stratum analysed, with the exception of patients aged <50 years and blacks. In the multivariate competing-risk analysis, the 2001-10 cohort experienced lower rates of WM-related (HR 0·57, 95% CI 0·49-0·66; P < 0·001) and non-WM-related deaths (HR 0·72, 95% CI 0·66-0·79; P < 0·001). In conclusion, there have been significant improvements in OS, WM-related and non-WM-related mortality in patients with WM diagnosed in the last decade.This publication has 28 references indexed in Scilit:
- Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results databaseBlood, 2014
- Outcome Disparities among Ethnic Subgroups of Waldenström's Macroglobulinemia: A Population-Based StudyOncology, 2014
- Population‐based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results databaseCancer, 2013
- Disparities in the Early Adoption of Chemoimmunotherapy for Diffuse Large B-cell Lymphoma in the United StatesCancer Epidemiology, Biomarkers & Prevention, 2012
- Examining racial differences in diffuse large B-cell lymphoma presentation and survivalLeukemia & Lymphoma, 2012
- No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 yearsAmerican Journal of Hematology, 2011
- The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)Leukemia, 2008
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958